Clinical Trial Update: A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. [Phase 1, Phase 2]

View source ↗

Summary

A single-arm, open-label clinical trial evaluating surufatinib combined with serplulimab, platinum, and etoposide in neuroendocrine carcinoma (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma

Drugs mentioned

• Etoposide (Etoposide)
• Platinum (Platinum-based chemotherapy)
• Serplulimab (serplulimab)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Neuroendocrine Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN